Participated · Equity · Apr 2026

Route 92 Medical develops neurovascular intervention technologies for acute ischemic stroke, notably the HiPoint Reperfusion System and its Monopoint approach to improve endovascular thrombectomy efficiency. The company completed the 250-patient SUMMIT MAX randomized trial, reporting strong safety and a high first pass effect rate. After submitting those results, the HiPoint Reperfusion System received FDA clearance in May 2025 for neurothrombectomy procedures. Route 92 has reported rapid growth in product adoption and an expanding commercial organization. With $50 million in new growth financing, the company intends to accelerate global commercial expansion, build clinical evidence for broader adoption, and continue investing in product innovation. Investors cited robust manufacturing capacity and a well-differentiated product portfolio as reasons for supporting the company’s next phase of growth.

Participated · Series C · Aug 2025

Iantrek develops minimally invasive surgical technologies and biologic tissue solutions aimed at restoring the eye’s natural fluid outflow pathways to treat chronic eye diseases such as glaucoma. The company launched its lead commercial product, AlloFlo Uveo, in October 2025 and has introduced AlloSpan Canal in the U.S. Iantrek positions its portfolio to offer complementary surgical solutions targeting both natural outflow pathways for a more comprehensive, physiologic approach to glaucoma intervention. Following a Series C in 2025 led by USVP, Sectoral, aMoon, and Visionary Ventures, Iantrek secured a $30 million debt facility from Trinity Capital to accelerate commercial expansion and advance its pipeline and regulatory work. The company plans to scale manufacturing and distribution capabilities and strengthen market access to broaden physician and patient adoption.

Participated · Series E · Mar 2025

Shoulder Innovations is a medical device company focused on shoulder arthroplasty that designs and commercializes implants and systems for shoulder replacement. Its core product platform centers on the patented InSet™ glenoid design, which testing has shown can significantly reduce glenoid implant micro-motion and simplifies the surgical technique, potentially reducing complications and increasing implant longevity. The company has also developed an anatomic reverse shoulder system designed to work with and maximize the available rotator cuff rather than substitute for it. Shoulder Innovations says it has expanded its product line and strengthened its sales organization and has emerged as a pure‑play leader in shoulder arthroplasty. Financially, the company closed a $40 million Series E equity financing led by U.S. Venture Partners to support commercialization and product development. Proceeds will be used primarily to advance commercialization of the InSet™ Total Shoulder and Reverse Shoulder Arthroplasty Systems, support new product development, and for general corporate purposes. Shoulder Innovations Inc. (SI) is a privately held medical device company based in Grand Rapids, Michigan and described as a leader in the shoulder replacement implant market. The company develops shoulder replacement implants and is supported by a broad team of innovators with experience in the shoulder space. SI announced it has closed an oversubscribed $42 million Series D financing. The financing round was led by Gilde Healthcare Partners. Returning investors included US Venture Partners, Lightstone Ventures and the cultivate (MD) Accelerator Capital fund; new investors include Gilmartin Capital and Aperture Venture Partners. The article does not disclose revenue, user metrics, or detailed use of proceeds. Shoulder Innovations develops a glenoid fixation solution for anatomic shoulder arthroplasty, commercialized as the InSet glenoid. Founded in 2009 and based in Holland, Mich., the company secured issued patents, 510(k) clearance and published multiple peer‑reviewed articles supporting the technology. In 2015 Genesis Innovation Group partnered with the company to provide capital and operational leadership, and Shoulder Innovations recorded its first commercial sale of the InSet glenoid in 2016. Continued investment led by Genesis and its cultivate(MD) Capital Funds and leadership from industry veterans supported ongoing growth and innovation. The company is led by CEO Rob Ball and has completed a $21.6M equity financing to further commercialization. The financing also prompted expansion of the board to six members, including new Series C representatives and two independent directors. Shoulder Innovations is a Holland, Mich.-based medical device company that develops and commercializes shoulder replacement systems. Led by Executive Chairman Rob Ball, the company leverages a patented inset glenoid design to commercialize a shoulder replacement implant system focused on improving outcomes related to glenoid loosening. It designs and commercializes innovative products aimed at improved patient care and reduced overall cost to the healthcare system. The company closed a $2.5M Series A equity funding round and intends to use the funds to accelerate new product development and to acquire inventory and assets to accelerate growth of its current Inset platform technology.

Led · Series C · Oct 2024

Evommune is a Palo Alto-based clinical-stage biotechnology company focused on discovering and developing treatments for immune-mediated inflammatory diseases. Led by CEO Luis Pena, its lead programs include EVO756, a potent, highly selective small-molecule antagonist of MRGPRX2, and EVO301, a long-acting serum albumin-binding injectable therapeutic fusion-protein targeting IL-18 signaling. EVO756 is implicated in mast cell activation and neuroinflammation and is being developed as a potentially targeted, safe oral therapy for multiple mast cell–mediated diseases. EVO301 is designed to neutralize IL-18 signaling to regulate inflammation across chronic inflammatory diseases. The company plans multiple Phase 2 studies of EVO756 and a Phase 2 proof-of-concept study of EVO301. Evommune raised $115M in a Series C and intends to use the proceeds to advance these lead clinical programs. Evommune is a private, clinical-stage R&D biotechnology company focused on treating inflammatory diseases. The company uses a human tissue–based approach to discover, develop, and deliver therapies intended to address symptoms and halt progressive disease. Led by President and CEO Luis Peña, Evommune pursues translational immunology research to advance its therapeutic candidates. Founded in 2020, the company is advancing its pipeline through clinical-stage development. Evommune recently expanded funding for its Series B round, strengthening its financial position for near-term work. The company intends to use the new funds to expand operations and broaden its business reach. Evommune is a clinical-stage biotechnology company discovering and developing therapies to treat inflammatory diseases using a dynamic human tissue-based approach. Its prioritized pipeline includes EVO101, a novel small-molecule IRAK4 inhibitor currently in a Phase 2a proof-of-concept trial for atopic dermatitis, with data expected later this year. The company is also developing EVO756, a preclinical program that targets mast cells by selectively modulating MRGPRX2 to treat chronic spontaneous urticaria and interstitial cystitis. In addition, Evommune runs a discovery program targeting autoimmune diseases via PKCθ. The company intends to use the proceeds from its recent financing to support these three prioritized programs. Evommune was founded in 2020 and is led by President and CEO Luis Peña in Palo Alto, CA. Evommune is a private R&D company and innovation engine that uses the skin as a lens to uncover approaches for accelerating development of medicines across immunology and dermatology. The company has four investigational compounds in its pipeline, three of which were in‑licensed via an exclusive agreement with Dermira, a wholly owned subsidiary of Eli Lilly and Company. Evommune is led by co‑founders Luis Pena (President & CEO), Eugene A. Bauer, M.D. (Chief Medical Officer), and Hans Hofland, PhD (SVP of Research). The company says it is developing transformative therapies to treat patients with immune‑mediated and chronic inflammatory diseases. Evommune recently won the Gore Range Capital Skin Health Innovation Competition at the Fall Clinical Dermatology Conference, reflecting engagement with clinicians and industry thought leaders. The company plans to use its recent funding to continue research and development of its pipeline. Evommune applies a tissue‑based, skin‑centered approach and a novel screening platform to discover molecules aimed at treating chronic inflammatory and dermatologic diseases. The company is building a pipeline intended to include both discovery-stage and clinical‑stage development programs and has established academic and industry collaborations to support that work. Leadership includes industry veterans Luis Peña (CEO), Eugene A. Bauer, MD (CMO), Hans Hofland, PhD (SVP, research), and Janice Drew, MPH (SVP, product development), who previously held senior roles at Dermira. The team highlights a track record of rapid regulatory approvals and drug development across immunology and dermatology; Dermira was sold to Eli Lilly for approximately $1.1 billion in 2020. Evommune says the seed financing will be used to set up and drive execution of its longer‑term strategy to accelerate development of transformative medicines. The company was founded in 2020 and is headquartered in Los Altos, California.

Participated · Series B · Apr 2024

Miach Orthopaedics develops the Bridge-Enhanced ACL Restoration (BEAR®) Implant, a bio‑engineered product that facilitates healing of torn anterior cruciate ligaments rather than replacing them. The BEAR Implant acts as a bridge between ACL ends, uses a small amount of the patient’s blood to promote healing, and is resorbed as the ligament repairs. It received De Novo FDA approval in December 2020 and is indicated for skeletally mature patients (14+) with a complete ACL rupture and an ACL stump attached to the tibia. The company reports the BEAR Implant has been used to treat nearly 3,000 patients. Miach says the technology is a paradigm shift from ACL reconstruction because it avoids graft harvest or donor tendons and preserves the ACL’s native attachments. Current priorities include U.S. commercial expansion and clinical initiatives such as the Bridge Registry to gather real‑world outcomes. The company is privately held and located in Westborough, Massachusetts. Miach Orthopaedics is a privately held company in Westborough, Massachusetts, focused on bio-engineered surgical implants for connective tissue restoration, initially commercializing the BEAR Implant for ACL repair. The BEAR Implant is a bridge-enhanced, bio‑engineered device that, when combined with a small amount of the patient’s blood, facilitates healing of a torn ACL and is resorbed as the ligament heals. The device received De Novo FDA approval in December 2020 and is the first medical technology with Level 1 clinical evidence showing it enables the body to heal a torn ACL. Commercial launch began in fall 2021; more than 500 patients have been treated with the BEAR Implant commercially. The company says the BEAR procedure avoids harvesting or using donor tendon grafts and preserves the ACL’s original attachments. The recent financing will fund ongoing operations and expand the U.S. commercial rollout to bring ACL restoration to more patients. MIACH Orthopaedics is focused on the Bridge-Enhanced® ACL Repair (BEAR®), a proprietary bio-engineered sponge used as a bridging scaffold to stimulate healing of torn anterior cruciate ligaments. The BEAR technology has been tested in nearly 100 human patients under an FDA Investigational Device Exemption (IDE). Preclinical studies and the company’s clinical work suggest the BEAR procedure avoids graft harvest and may lower long-term arthritis risk versus conventional ACL reconstruction. MIACH plans to use new funding to accelerate manufacturing capabilities and continue U.S. clinical trials of BEAR. The company has received initial research funding from the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health. MIACH is a privately held company located in Boston, Massachusetts.